Rallybio Corp (NASDAQ:RLYB) — Market Cap & Net Worth
Market Cap & Net Worth: Rallybio Corp (RLYB)
Rallybio Corp (NASDAQ:RLYB) has a market capitalization of $85.82 Million ($85.82 Million) as of September 18, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #19853 globally and #4534 in its home market, demonstrating a 1.12% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Rallybio Corp's stock price $17.16 by its total outstanding shares 5310499 (5.31 Million). Also see Rallybio Corp balance sheet assets for a full breakdown of the balance sheet.
Rallybio Corp Market Cap History: 2021 to 2026
Rallybio Corp's market capitalization history from 2021 to 2026. Data shows growth from $50.66 Million to $91.13 Million (3.90% CAGR). Also see Rallybio Corp operating cash flow efficiency for how efficiently the company converts equity into cash flow.
Index Memberships
Rallybio Corp is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.67 Trillion | 0.00% | #565 of 976 |
|
NASDAQ Composite
IXIC
|
$41.95 Trillion | 0.00% | #1916 of 3165 |
Weight: Rallybio Corp's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Rallybio Corp Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Rallybio Corp's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Check Rallybio Corp stock price for real-time trading data and today's change.
Latest Price to Sales (P/S) Ratio
4.25x
Rallybio Corp's market cap is 4.25 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2024 | $5.10 Million | $636.00K | -$57.77 Million | 8.02x | N/A |
| 2025 | $3.64 Million | $858.00K | -$8.98 Million | 4.25x | N/A |
Competitor Companies of RLYB by Market Capitalization
Companies near Rallybio Corp in the global market cap rankings as of September 18, 2026. Review tangible equity quality of Rallybio Corp to assess the quality of the company's equity after excluding intangible assets.
Key companies related to Rallybio Corp by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #185 globally with a market cap of $130.87 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #337 globally with a market cap of $79.84 Billion USD.
- CSL Ltd (AU:CSL): Ranked #455 globally with a market cap of $60.95 Billion USD ( AU$86.14 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #504 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #185 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.87 Billion | $516.34 |
| #337 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $79.84 Billion | $789.45 |
| #455 | CSL Ltd | AU:CSL | $60.95 Billion | AU$177.56 |
| #504 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $158.07 |
Rallybio Corp Historical Marketcap From 2021 to 2026
Between 2021 and today, Rallybio Corp's market cap moved from $50.66 Million to $ 91.13 Million, with a yearly change of 3.90%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $91.13 Million | +2401.09% |
| 2025 | $3.64 Million | -28.53% |
| 2024 | $5.10 Million | -59.83% |
| 2023 | $12.69 Million | -63.62% |
| 2022 | $34.89 Million | -31.13% |
| 2021 | $50.66 Million | -- |
End of Day Market Cap According to Different Sources
On Sep 18th, 2026 the market cap of Rallybio Corp was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $85.82 Million USD |
| MoneyControl | $85.82 Million USD |
| MarketWatch | $85.82 Million USD |
| marketcap.company | $85.82 Million USD |
| Reuters | $85.82 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Rallybio Corp
Rallybio Corporation, a clinical-stage biotechnology company, engages in the development and commercialization of life-transforming therapies for patients suffering from severe and rare diseases. Its lead product candidate is the RLYB116, an inhibitor of complement component 5 (C5) to treat several diseases of complement dysregulation which has completed phase 1 trial; and RLYB332, a preclinical … Read more